Now this is a part of the article I hope is correct>>>>>>>Castello said Xoma has no plans for new financing deals in 2004, but is in serious discussions with other firms regarding potential new partnerships.
As soon as the FDA approves the drug, Xoma intends to begin testing four or five other uses for Raptiva, Castello said. Those would include other autoimmune diseases, such as lupus, multiple sclerosis and organ transplantation.
"It's really a case of which to choose next," Castello said. Xoma dropped studies of Raptiva for kidney transplantation, but the company, Castello said, could pick that up again, perhaps in "a year or so."
Xoma and Genentech also hope to have data on a Phase II trial of Raptiva for psoriatic arthritis by the end of the year, and then determine whether to enter Phase III trials. Separately, Xoma plans to enter the clinic this fall with two others drugs, one for acne and another for vascular inflammation.
"We're going to be a busy bunch," Castello said.<<<<<<<<<<<<<<<<<<<
Busy bunch............has a real nice ring to it. |
